Calcium-sensing receptor gene (CASR) polymorphisms and CASR transcript level concerning dyslipidemia in hemodialysis patients: a cross-sectional study

Table 2 CASR rs1801725 and dyslipidemia in patients not receiving lipid-lowering medication

Genotypes, MAF, HWE	Patients with dyslipidemia diagnosed with non-HDL-cholesterol ≥ 130 mg/dL and TG ≥ 200 mg/dL	Patients without dyslipidemia diagnosed with non-HDL-cholesterol ≥ 130 mg/dL and TG ≥ 200 mg/dL	Comparison of patients with dyslipidemia diagnosed with non-HDL-cholesterol ≥ 130 mg/dL and TG ≥ 200 mg/dL and without dyslipidemia of this type Odds ratio (95% CI), P-value¹	Patients without any dyslipidemia	Comparison of patients with dyslipidemia diagnosed with non-HDL-cholesterol ≥ 130 mg/dL and TG ≥ 200 mg/dL and without any dyslipidemia Odds ratio (95% CI), P-value¹
P_trend² = 0.010, _Pgenotype ^1,3 = 0.026				P_trend² = 0.023, _Pgenotype ^1,3 = 0.060
GG	92 (78.6)	386 (67.8)	Reference	159 (68.5)	Reference
GT	25 (21.4)	169 (29.7)	0.621 (0.385–1.001), 0.049	67 (28.9)	0.645 (0.381–1.091), 0.101
TT	0 (0)	14 (2.5)	0.144 (0.009–2.437), 0.083³	6 (2.6)	0.133 (0.007–2.381), 0.091³
TT + GT vs GG	25 (21.4)	183 (32.2)	0.573 (0.356–0.922), 0.021	73 (31.5)	0.592 (0.351–0.997), 0.048
TT vs GG + GT	0 (0)	14 (2.5)	0.163 (0.010–2.752), 0.144³	6 (2.6)	0.148 (0.008–2.655), 0.185³
MAF	(0.11)	(0.17)	0.571 (0.367–0.889), 0.012	(0.17)	0.583 (0.361–0.942), 0.026
P-value for HWE	0.196	0.372		0.736

Significant differences are indicated using a bold font.
1 – Pearson’s chi-squared test; 2 – Cochran-Armitage trend test, 3 – Fisher’s test

ISSN: 1471-2369